Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
November 7, 2024

Plus Therapeutics partners with SpectronRx for CNS therapy development

Plus Therapeutics has entered into a manufacturing services agreement (MSA) with SpectronRx to produce the radiotherapy, Rhenium (186Re) Obisbemeda, for central nervous system (CNS) cancers.

The collaboration is set to accelerate supply chain redundancy for the production of Rhenium (186Re) Obisbemeda. Credit: National Cancer Institute on Unsplash.